BDSC Company to distribute CorDx Flu A/B & COVID-19 At-Home Rapid Test

BDSC Company, and CorDx announced that CorDx recently received Emergency Use Authorization for its CorDx Tyfast Flu A/B and COVID-19 At Home Rapid Test, which BDSC will distribute in North America.

The 3-in-1 self-test is a lateral flow immunoassay device intended for the qualitative detection and differentiation of nucleocapsid protein antigens from influenza type A and type B as well as SARS-CoV-2. A sample is collected with one shallow nasal swab from those suspected of respiratory viral infection. This new at-home diagnostic solution sets the standard for detecting and distinguishing between Flu A, Flu B, and COVID-19 in 10 minutes. 

[Read more: Walgreens releases 2023-2024 flu index]

“This test is truly a game changer for every household. The ability to accurately test for Flu A, Flu B, and COVID with a single shallow nasal swab in a few short minutes gives every individual the control to determine their next step regarding their personal care. We could not be more excited to align with the CorDx team to bring this product to the US Market,” said Richard Doughty, president andCEO of BDSC.